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Background: Renal cell carcinoma (RCC) is a complex with diverse biological characteristics and distinct molecular
signature. New target therapies to molecules that drive RCC initiation and progression have achieved promising
responses in some patients, but the total effective rate is still far from satisfaction. Dachshund (DACH1) network is a
key signaling pathway for kidney development and has recently been identified as a tumor suppressor in several
cancer types. However, its role in renal cell carcinoma has not been fully investigated.
Methods: Immunohistochemical staining for DACH1, PCNA and cyclin D1 was performed on human renal tissue
microaraays and correlation with clinic-pathological characteristics was analyzed. In vitro proliferation, apoptosis
and in vivo tumor growth were evaluated on human renal cancer cell lines with decitabine treatment or ectopic
expression of DACH1. Downstream targets and potential molecular mechanism were investigated through western
blot, immunoprecipitation and reporter gene assays.
Results: Expression of DACH1 was significantly decreased in human renal carcinoma tissue. DACH1 protein
abundance was inversely correlated with the expression of PCNA and cyclin D1, tumor grade, and TNM stage.
Restoration of DACH1 function in renal clear cell cancer cells inhibited in vitro cellular proliferation, S phase
progression, clone formation, and in vivo tumor growth. In mechanism, DACH1 repressed cyclin D1 transcription
through association with AP-1 protein.
Conclusion: Our results indicated that DACH1 was a novel molecular marker of RCC and it attributed to the
malignant behavior of renal cancer cells. Re-activation of DACH1 may represent a potential therapeutic strategy.
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Renal cell carcinoma (RCC) is the most lethal type of
genitourinary cancer and its incidence has been
increased worldwidely [1]. Lacking specific markers
makes early diagnosis difficult. Prognosis for advanced
RCC is poor because of highly metastatic and generally
resistant to conventional chemotherapy and radiotherapy
[2]. With the growing understanding of renal cancer
biology, new agents targeting specific growth pathways have
been developed. The mammalian target of rapamycin
(mTOR), a serine/threonine protein kinase, regulates cell* Correspondence: kmwu@tjh.tjmu.edu.cn
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unless otherwise stated.growth, division, and survival. Clinically, mTOR inhibitors
have clearly shown survival advantage than interferon-alpha
[3]. Most renal clear cell carcinomas showed enhanced
angiogenesis, and targeting vascular endothelial growth
factor (VEGF) with either tyrosine kinas inhibitors or
anti-VEGF monoclonal antibody also demonstrated super-
ior activity in comparison to traditional chemotherapies [4].
However, even treated with the newest targeted therapeutic
agents, metastatic RCC will progress in all patients due to
primary or secondary resistance [5]. Obviously, RCC is a
complex with diverse biological characteristics and distinct
molecular signature. Many other biological factors may
influence the therapeutical response of RCC. Accurate
pathological characterization will guide the clinical
management of RCC. Therefore, new molecular markers. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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therapy for personalized medicine can further bring
survival benefits [6,7].
The characterization of renal cell carcinoma based on
gene expression patterns has the potential to supply
significant biological and clinical insights. Kidney
cancers show aberrant methylation and methylation
profiles can be predictive of adverse prognosis [8]. DNA
hypermethylation in CpG islands of promoter region
usually results in transcriptional silencing, a common
mechanism leading to the inactivation of tumor suppressor.
In the search for novel epigenetic markers for clear cell
renal cell carcinoma, Dr. Dalgin’s group found DACH1 was
among the 6 down-regulated genes with hypermethylation
of promoter region [9].
DACH1, originally discovered in drosophila eye develop-
ment, is an essential member of Retinal Determination
Gene Network (RDGN) [10]. RDGN mainly consists of
Dach, Eya and Six family members. Balanced functions of
RDGN are essential for normal development of many
organs, including kidney and ear [11]. Recently, altered
expressions or activity of the RDGN has been documented
in a variety of malignancies [12-14]. Generally, DACH1
behaves as a tumor suppressor, and its expression is
reduced in several cancers. The ectopic expression of
DACH1 inhibits cellular proliferation in vitro and tumor
growth in vivo [15-23]. On the other hand, Six and Eya are
frequently overexpressed and promote proliferation,
invasion and tumorigenesis [24-28]. It is important
that expression level of DACH1 can predict survival
in breast cancer [15,29]. RNA protection assay and
northern blot indicated that DACH1 was richly expressed
in embryonal kidney cells and adult kidney tissues, but
dramatically decreased in two renal cancer cells [30].
Epigenetic silencing of DACH1 mRNA was also observed
in renal cancer tissues [9]. However, there were no
experimental evidence and detailed clinic studies to
examine the role of DACH1 in renal cancer initiation
and progression. The biological function and downstream
targets of DACH1 are cell context-dependent. For
example, the paracrine signal repressed by DACH1 in
glioma stem cells was FGF2 [19]; while DACH1 targets
IL-8 in breast cancer cells [17]. The clinical significance
and downstream signaling of DACH1 in RCC remain to
be experimentally answered. The current study was
conducted to analyze the DACH1 expression in relation to
clinic-pathological characteristics and identify molecular
targets of DACH1 in renal cancers.
Results
Decreased expression of DACH1 correlates with tumor
progression in renal cancer tissues
As a potential tumor suppressor, DACH1 promoted hyper-
methylation and correspondingly reduced expression ofDACH1 was observed in several kinds of cancers, including
esophageal cancer, gastric cancer, colorectal cancer and
hepatocellular carcinoma [20,22,31,32]. Epigenetics changes
in 38 matched renal clear cell carcinoma and normal
tissues demonstrated that DACH1 promoter region
was hypermethylated in renal cell carcinoma [9]. To
the best of our knowledge, there were no reports that
comparing DACH1 protein abundance between renal
normal and cancerous tissues. We used a well validated
DACH1 polyclonal antibody to detect DACH1 expression
in human renal tissue microarrays consisting of normal
and different types of cancers by immunohistochemical
staining. DACH1 was highly expressed in the nuclei of
renal tubular cells. Although RCC originates from the
tubule of kidney, DACH1 expression was markedly
decreased in all 3 major types of renal cancers, including
clear cell renal carcinoma and granular cell carcinoma
(Figure 1A, B). Further analysis showed that DACH
protein intensity was gradually reduced with the tumor
progression. More than 85% tissues in T3/T4 tumors
showed no or very weak expression(grade 0 or 1); while in
early-stage tumors (T1), 65% tissues had medium or
strong expression (grade 2 or 3) (Figure 1C). Moreover, on
average 60% of cells in low grade cancers (grade I)
expressed DACH1, less than 20% cells in grade III tumors
had detectable DACH1 expression (Figure 1D). Thus the
DACH1 expression was significantly reduced in cancer
tissues, correlated inversely with the tumor grade and
stage. Since the high proliferation is a hallmarker of cancer
cells and DACH1 was reported to inhibit tumor growth
in vivo in a series of xenograft models [15,19,23], we
examined PCNA expression, a surrogate marker of
cellular proliferation, in a series of sections from the same
sample. In consistence with previous reports, PCNA
was positively related to the tumor grade (Figure 1E).
Importantly, co-expression analysis demonstrated reverse
relationship between protein expression of DACH1 and
PCNA in renal cancer tissues (Figure 1F). In order to
further investigate the relationship of DACH1 and PCNA
at mRNA level, we examined Oncomine database. The
mRNA profiles GSE14994 consisting of 70 patients with
renal cancers showed that DACH1 and PCNA were
inversely correlated (Figure 1G) (p < 0.002). Therefore,
we conclude that the lost expression of DACH1 led
to higher cellular proliferation in renal cancer tissues.
Reactivation of DACH1 expression by methylation
inhibitor reduced renal cancer cellular proliferation
DACH1 mRNA was highly expressed in several adult tissues
including kidney, heart, lung and brain, with the highest
expression detected in adult kidney tissues [30]. Using the
embryo kidney cell (HEK293) as positive control, we deter-
mined DACH1 abundance in two clear cell cancer lines
ACHN and CAKI. Western blot showed that DACH1 was























































































































































Figure 1 DACH1 expression decreased in renal cell carcinoma and inversely correlated with PCNA. A. Representative expression of DACH1 in
normal kidney tissues and renal clear cell carcinomas. Intensity of DACH1 protein in relation to tumor type (B) and tumor stage (C). D. The ratio of
DACH1 positive cells with tumor grade. E. Ratio of PCNA positive cells with tumor grade. F. Relative protein abundance of DACH1 with PCNA.
G. Reciprocal quantitave mRNA expression of DACH1 and PCNA in renal clear cell carcinoma tissues from Oncomine database GSE14994.
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DACH1 was abundantly expressed in HEK293 cells
(Figure 2A). After sequentially treated with Decitabine in
combination with Trichostatin A (TSA), DACH1 mRNA
was induced about 3 folds increase (Figure 2B). Correspond-
ingly, DACH1 protein was increased about 5 folds
(Figure 2C). Cellular proliferation ability was evaluated in
ACHN cells treated with Decitabine and TSA. Both MTT
assay and cell counting demonstrated that combined treat-
ment reduced the cancer growth rate (Figure 2D, E). Those
results indicated that epigenetic silencing of endogenous
DACH1 contributed to the enhanced growth of RCC cells.
Ectopic expression of DACH1 inhibited renal cancer cell
in vitro proliferation and in vivo tumor growth
In order to directly define the function of DACH1, we
established sublines through infecting ACHN and CAKIcells with retrovirus expressing DACH1. Two weeks
after antibiotic selection, more than 90% cells expressed
Flag-tag DACH1 as shown by fluorescent staining
(Figure 3A, B). Expression of DACH1 decreased the cell
proliferation in both ACHN and CAKI cells (Figure 3C, D).
Flow cytometry revealed that the decrease in S phase was
corresponded to the increase in G1 (Figure 3E). However,
there was no statistical difference in apoptotic cells
with or without DACH1 expression (Figure 3F). The
clone formation is a basic characteristic of transformed cells
and represents the malignant potential and tumorigenicity.
Engineering expression of wild type DACH1 inhibited the
clone number in both ACHN and CAKI cells, in contrast,
expressing a DACH1 with DS domain deleted mutant had
no repressive function (Figure 4A, B, C). In order to further
evaluate tumorigenecity in vivo, CAKI cells expressing
DACH1 and the vector control were subcutaneously
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Figure 2 Epigenetic silencing of DACH1 enhanced cellular proliferation. A. Western blot analysis of DACH1 and cyclin D in embryo kidney
cells and clear cancer cells. B. Relative DACH1 mRNA expression normalized to GAPDH with or without treatment. C. Protein abundance with or
without treatment. β-tubulin as loading control. Cellular proliferation analyzed by MTT assay (D) and cell counting (E).
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growth was monitored twice a week. The growth
curve revealed a dramatic decrease of tumor size in the
CAKI group following DACH1 expression (Figure 4D).
The average tumor weight decreased from 320 mg in
the control group to 50 mg in the DACH1 group
(Figure 4E, F). Moreover, gross observation indicated
that cancer cells in vector group infiltrated into surround-
ing host tissues, while tumors in DACH1 group was not
only smaller, but also clearly separated from surrounding
host tissues.
DACH1 repressed cyclin D1 in vitro and in vivo
Previous studies proved that RDGN integrated with cell cycle
regulatory machinery to modulate cellular proliferation and
tumorigenecity in several types of cancers [15,24,33-35].
Specifically, Six1 and EYA1 upregulated cyclin D; In contrast,
DACH1 acted as an antagonist of cyclin D1 in breast cancer.
We searched in Oncomine database to find whether this
reciprocal relation exists in renal cancer. Quantitative mRNA
expression from 20 pairs of normal and cancerous tissues
showed that higher DACH1 expression is accompanied with
lower cyclin D1 expression in normal renal tissue. However,
DACH1 was reduced more than 80% in cancerous tissues
with up to 6 folds increase in cyclin D (Figure 5A). The
reverse correlation was observed in each sample from two
different databases (Figure 5B, C). To further explore
their relationship in the protein level, human renal cancertissue microarrays were immunostained with antibodies
for DACH1 and cyclin D1. Very few cells were positive for
cyclin D1 in normal renal tissue, and cancer cells
expressed cyclin D1 at different ratio (Figure 5D). The
ratio of cyclin D1 positive cells statistically increased
with the tumor grade (Figure 5E). Moreover, the higher
expression of DACH1 usually accompanied with the lower
expression of cyclin D1, with coefficient R value of −0.64
(p < 0.01) (Figure 5F).
The cyclin D1 and related cell cycle protein RB and
CDK4 were measured in cultured renal cancer cell lines.
Western blot results demonstrated that ectopic expression
of wild type DACH1 dramatically repressed cyclin D1 and
phosphorylated RB proteins, but it had no effect on CDK4
in both ACHN and CAKI cells (Figure 6A, B). RT-PCR
demonstrated about 50% decrease of cyclin D1 mRNA in
CAKI cells expressing DACH1 (Figure 6C). To measure
the transcriptional regulation of cyclin D1, transient
co-transfection assay was performed in ACHN and
CAKI cells using DACH1 expressing vector and cyclin
D1 promoter constructs linked with luciferase (Figure 6D).
As a positive control, serum activated cyclin D1 promoter
activity was increased about 5–6 folds; while DACH1
reduced cyclin D1 promoter activity to less than 50%.
However, a DS domain with deleted mutants abrogated
repressive function (Figure 6E, F). Immunoprecipitation
with anti-flag antibody and western blot using a c-Jun
























































































































Figure 3 Ectopic expression of DACH1 inhibited cellular proliferation. Stable expression of Flag-taged DACH1 in renal cancer cell lines
ACHN (A) and CAKI (B). DNA synthesis evaluated by H3-TdR incorporation (C) and BrdU incorporation (D). Proliferation evaluated by S phase entry
(E) and apoptosis evaluated by Annexin-V stanining (F).
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Chromatin immunoprecipitation with a flag antibody and
PCR amplified human cyclin D1 promoter sequence
supported a model that DACH1 was recruited into cyclin
D1 promoter context at AP-1 site, as previously observed
in human breast cancer (Figure 6H) [15].Discussion
The current studies intended to demonstrate DACH1
protein expression was significantly reduced in RCC
tissues in comparison to normal kidney tissues. Moreover,
the DACH1 protein level inversely correlated with



































































































Figure 4 DACH1 inhibited clone formation and tumor growth in vivo. A. Representative images of clone formation. Relative clone formation
efficiency of 3 experiments for ACHN (B) and CAKI (C). D. Tumor growth curve of subcutaneously implanted CAKI cells. E. The tumor weight after
45 days. F. Images of tumors from CAKI cells with or without DACH1 expression.
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tissues was 80% less than the matched normal kidney
tissues due to the hypermethylation of DACH1 promoter
region [9]. This finding was also in accordance with most
observations in solid tumors and further supported
the concept that DACH1 represented a novel tumor
suppressor [15,16,19-21]. Functional inactivation of tumor
suppressors by promoter methylation is a common
mechanism of tumorigenesis. Histone deacetylase inhibitors
(HDACI) had great anti-cancer effect in a wide range of
cancers in preclinic studies and exhibited promising
responses in patients with various cancer types [36]. In this
respect, CDF, a new synthetic analogue of curcumin, had
been demonstrated as a novel demethylating agent for
restoring the expresson of hyper-methylated gene and
caused a marked inhibition of cellular growth [37]. We
showed that decitabine treatment induced the expression
of DACH1 and inhibited cellular proliferation. However,
whether DACH1 is the key target of decitabine for in vivo
tumor growth needs to be further evaluated. In contrary to
epigenetic changes and mRNA expression, previous studies
failed to reveal the decreased protein abundance of
DACH1 in cancer tissues [9]. DACH1 has 3 isoforms
and its isoform expressions showed a tissue-specificpattern [23]. Both antibody specification and isoform
expression may account to this discrepancy.
Previously, we showed that DACH1 was lost in triple
negative breast cancers associated with stem cell
property, and high expression of DACH1 predicted a
40-month survival advantage in all types of breast
cancer [15]. Recently, Dr. Powe’s study demonstrated that
high expression of DACH predicted a better survival in
luminal breast cancers [29], further supporting our
previous report. However, the prognostic value of DACH1
in RCC remains to be elucidated.
Our studies demonstrated that the expression of
DACH1 inversely correlated with cyclin D1 and PCNA,
the surrogated markers of proliferation. It suggested that
the loss of DACH1 led to a growth advantage of tumor
cells. The sequential epigenetic treatment with epigenetic
modification agents decitabine/TSA induced DACH1
expression accompanied with decreased proliferation,
providing a laboratory evidence to support the concept
that inactivation of DACH1 contributed to tumor growth.
Indeed, the engineering expression of DACH1 inhibited
cell growth via the reduced DNA synthesis, not the altered
apoptosis, depending on the DS domain. Our results were
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Figure 5 DACH1 inversely correlated with cyclin D1 in renal cancer tissues. A. Quantitative mRNA expression of DACH1 and cyclin D1 in
normal renal tissues and renal carcinomas. Reciprocal expression of DACH1 and cyclin D1 from Oncomine database GSE6344 (B) and GSE14994
(C). D. Representative image of cyclin D1 in normal renal tissues and clear cell carcinoma tissues. E. Cyclin D1 expression with tumor grade.
F. Reciprocal protein abundance of DACH1 and cyclin D1.
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the key DS domain. The DS domain has been proved to
be required for a series of important functions, including
the regulation of cancer stem cell expansion [38], AR
[16], IL-8 secretion and breast cancer cell invasion
[17]. Transcriptional repression of AP-1 family members
c-jun and c-fos by DACH1 also required the conserved
N-terminal DS domain. The deletion of DS domain
abolished the repression of Cyclin D1 in breast cancer and
the overexpression of DS domain alone substituted
DACH1 to repress S phase entry in breast cancer cells
[15]. At the molecular level, the DS damin alone can be
recruited to the cyclin D1 promoter AP site. In association
with AP-1 and smads complex, DS domain possessed
DNA binding property [18]. DACH1 antagonized FOXM1
signaling through competitively binding to the conserved
forehead specific DNA sequence [18]. Together, those
experiments demonstrated that DACH1 DS domainand its associated proteins play key role in the
DACH1-mediated function. Molecules or reagents
targeting to this portion of DACH1 may have potential
therapeutical applications.
The cyclin D1 gene encoded the regulatory subunit of
a holoenzyme that phosphorylated and inactivated the
pRb protein, thereby promoting the DNA synthesis and
the S phase entry. Aberrations in the G1/S transition
of cell cycle were observed in many cancers. pVHL
downregulated cyclinD1 through HIF-independent mecha-
nisms [39], therefore, conventional RCC often expressed
high cyclin D1 protein level [40]. Cyclin D1 was a key
downstreaming target of mTOR. In RCC cell line CAKI
and ACHN, dual inhibition of src kinase and receptor
tyrosine kinase resulted in synergistic inhibition of prolifer-
ation and migration, accompanied with suppression of cyc-
lin D1 [41]. Moreover, tyrosine kinase inhibitor, sorafenib,
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Figure 6 DACH1 in association with c-Jun to repress cyclin D1 transcription. Western blot analysis of ACHN (A) and CAKI (B) cells
expressing DACH1 wt, DS or vector control. C. RT-PCR detected cylin D1 and DACH1 mRNA abundance. D. Schematic structure of DACH1 and
cylin D1 promoter. E. Luciferase activity of cyclin D1 promoter in renal cancer cell line CAKI (E) and ACHN (F). G. Immunoprecipitation and
western blot of CAKI cells. H. ChIP of cyclin D1 promoter AP-1 site in CAKI cells.
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and tumor growth of RCC cell lines 786-O and OS-RC-2,
also with down-regulating of cyclin D1 expression and cell
cycle arrest [43]. Experimentally, exposure of human
renal cells to recombinant erythropoietin induced
cellular proliferation through stimulating the expression
of cyclin D1 while inhibiting the expression of p21cip1 and
p27kip1 [44]. Approximately 75% of the RCC tumors
expressed higher level of cyclin D1 than the normal
kidney context. Surprisingly, previous studies did notfind cyclin D1 expression correlated with proliferation, as
determined by Ki-67 or s-phase analysis [45].
The abundance of cyclin D1 was regulated through dis-
tinct mechanisms, including post translational modification
by phosphorylation and the induction of mRNA and/or
gene transcription. Our data indicated DACH1 repressed
cyclin D1 transcription, as determined by RT-PCR and
promoter activity assays. Recent studies revealed multiple
novel functions of cyclin D1, including cancer stem cell
self-renewal [46], VEGF-stimulated vascularization [47]
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the common downstream target of multiple signaling
in RCC target therapy, the current studies raised the
possibility that expression level of DACH1 may determine
targeting therapeutic sensitivity either directly or indirectly,
therefore, affect the long term survival.
p53 is a powerful tumor suppressor and small molecules
that activated p53 had shown promising anti-tumor
effects in hematological malignancies [49]. Recent findings
that DACH1 associated with and enhanced p53 function
to induced apoptosis provided an alternative mechanism
for DACH1 to inhibit tumorigenesis [21]. However, as a
new tumor suppressor, detailed targets of DACH1 and its
crosslinks with other oncogene/tumor suppressors remain
to be further clarified.
Materials and methods
The study protocol was approved by the ethics committee
of Tongji Medical College of Huazhong University of
Science and Technology.
Cell culture
Human renal clear cell carcinoma cell lines CAKI-1
were cultured in McCoy’s 5A medium with 10% fetal
bovine serum. ACHN cells were cultured in EMEM
supplemented with 2 mM L-glutamine, 1% non-essential
amino acids, 1 mM sodium pyruvate, and 10% fetal bovine
serum. Human embryonic kidney 293 cells (HEK293)
were maintained in DMEM containing 1% penicillin/
streptomycin and supplemented with 10% FBS.
Plasmid construction, stable cells, reporter genes, DNA
transfection and luciferase assay
Expression plasmids for DACH1 and DACH1 DS
domain deleted mutation (ΔDS) in pKW10 vector were a
gift from Dr. Cvekl [50]. After digestion with ClaI/EcoRV,
the insert was subcloned into a retrovirus expression
vector. Stable sublines expressing DACH1, ΔDS and
empty vector control were established by transient co-
transfection of DACH1-expressing vector with package
plasmids in HEK293T cells. At 36 h and 48 h after trans-
fection, the culture medium was collected and filtered
through a 0.45 μm filter for infecting renal cancer cells in
the presence of 8 mg/ml polybrene. The pool of trans-
duced cancer cells was further selected by treatment with
Blastcidin at 5ug/ml for 2 weeks. Human cyclin D1
promoter constructs were a gift from Dr. Pestell [15].
Plasmid DNA transfection and luciferase assays were
performed as previously described [15].
RNA isolation, RT-PCR and quantitative real-time PCR
Total RNA was isolated from CAKI cells stably expressing
DACH1 and vector control using the TRIzol reagent
(Invitrogen) following the manufacturer’s instructions.Five micrograms of total RNA was subjected to DNase
treatment and purification following RNA minipre kit
(Qiagen). cDNA was synthesized using the SuperScript II
Reverse Transcriptase Kit (Invitrogen). RT-PCR primers
for cyclin D1 were: 5’-GTGCTGCGAAGTGGAAACC -3’
and 5’- ATCCAGGTGGCGACGATCT-3’ [33]; primers
for DACH1 were: 5’-CCA TGA GCA ACT ATC ATG
CC-3’and 5’-TGT CCA TGC CCA GTT AGA GA-3’
[16]. Internal control primers for GAPDH were 5’-
ATCTTCCAGGAGCGAGACCCC-3’ and 5’- TCCAC
AATGCCAAAGTTGTCATGG-3’.
Immunohistochemistry and immunofluorescence
Human kidney cancer tissue arrays were purchased
from Alenabio (Xi’an, China), including 13 cases of
normal renal tissues, 5 cases of cancer adjacent normal
renal tissue, 55 cases of clear cell carcinoma tissue, 31 cases
of granular cell carcinoma tissue, and 19 cases of transi-
tional cell carcinoma tissue. Tumor tissues were sub-
grouped as grade I, well-differentiated; grade II, moderately
differentiated; and grade III, poorly or undifferentiated.
TNM status was as follows: 66 cases of T1N0M0, 33 cases
of T2N0M0, 9 cases of T3N0M0 and 2 cases of T4N0M0.
Tissue immunohistochemical stains were performed by
core facility using a streptavidin-biotin technique and semi-
quantated as described [51]. The antibodies were polyclonal
antibody to DACH1(Proteintech, 10914–1), to PCNA
(Santa Cruz, sc-7907) and monoclonal antibody to Cyclin
D1 (Santa Cruz, sc-20044). The immune stain intensity and
ratio of positive cells were analyzed. Immunofluorescence
staining for DACH1 was modified from published method
[52]. Cells were fixed in 4% formaldehyde for 10 minutes,
permeable by 1% Triton X-100 for 5 minutes then blocked
in 5% goat serum for 1 hour. Primary anti-Flag antibody
(M2, Sigma, F3165) was used at 1:200 dilution, the goat
anti-mouse secondary antibody (Alexa Fluor-568) was
used at 1:500. Cell nuclei were count-stained with
4,6-diamidino-2-phenylindole(DAPI).
Western blot, immunoprecipitation and
chromatin-immunoprecipitation study
Cultured cells at 90% confluence were pelleted and lysed
in RIPA Buffer (150 M NaCl, 20 mM Tris-HCI, 1 mM
EDTA, 1 mM EGTA, 1 mM Na3VO3, 2.5 mM sodium
pyrophosphate, 1 mM β-glycerophosphate, 1% Triton
x-100), supplemented with protease inhibitors. Protein
was separated by a 10% SDS PAGE and antibodies
used in Western blot included cyclin D1 (sc-20044),
CDK4 (sc-601), c-Jun (sc-1694), pRBser807 (Sigma, R3903),
and β-actin (sc-47778) as an internal loading control.
Immunoprecipitation for protein complex of DACH1
and c-Jun and in renal cancer cells was performed as
previously described [15]. Chromatin immunoprecipitation
(ChIP) was performed using published method [24]. The
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follows: AP-1 site:5’-GGCAGAGGGGACTAA TATTTC
CAGCA-3’ and 5’-GAATGGAAAGCTGAGAAACAGT
GATCTCC-3’. Immunoprecipitation with IgG was used as
negative control.Cell proliferation and apoptosis assay
Cells expressing DACH1, ΔDS and vector control were
seeded into 96-well plates in normal growth medium, and
cell growth was measured by daily3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium (MTT) assay as previously
described [53]. For measuring the growth curve, cells were
seeded into 12-well plates and serially counted for 6
to 7 days. DNA synthesis was analyzed by 3H-TdR
incorporation. Briefly, 1 × 105 cells were plated into
24-well plate and cultured for 36 hours. 3H-TdR
(1 μCi/well) was added to each well and the culture
was continued for another 2 hours. Cells were washed
twice with cold PBS and proteins were precipitated by
incubation with 10% trichloroacetic acid for 30 minutes at
room temperature (100 μL/well). After additional washes,
cells were treated with 0.2 N NaOH and collected in
scintillation vials. For 5-Bromo-29-Deoxyuridine (BrdU)
staining, cells were labeled with 100 μM BrdU for 1 hour
in regular culture medium, washed 3 times with PBS, fixed
in 3.7% formaldehyde/PBS for 10 minutes, treated with
4 N HCl/1% Triton-X100 for 10 minutes, and finally
washed 3 times with 0.1% NP-40/PBS. The cell suspension
was incubated with mouse anti-BrdU (Sigma, B8434) at
1:1000 for 2 hours at room temperature and stained with
goat anti-mouse antibody (AlexaFluor 568) at 1:1000
after washing. 10,000 cells were analyzed using a flow
cytometer (BD Biosciences). Apoptotic cells were measured
using a BD Pharmingen AnnexinV-PE Apoptosis Kit
following the standard protocol.Cell cycle
Cultured cells were processed by standard methods using
propidium iodide staining of cellular DNA. Samples were
conducted on a FACScan flow cytometer (BD Biosciences)
equipped with a 488-nm laser. Histograms were analyzed
for cell cycle compartments using ModFit version 2.0
(Verity Software House, Topsham, ME). A minimum of
20,000 events for each sample were collected for statistical
analysis.Colony formation assay
For contact-dependent growth, 4 × 103 renal cancer cells
were plated in triplicate into 6 cm dish and medium was
changed every 3 days. The colonies after 2-week growth
were visualized by staining with 0.04% crystal violet in
methanol for 1 hour [16].Tumor implantation study
A total of 2 × 105 CAKI cells expressing either vector
control or DACH1 were implanted subcutaneously to
6-week old ethymic male nude mice. The tumor growth
was measured weekly for 4 to 5 weeks using a digital
caliper. Tumor mass was weighted after mice were
sacrificed. The study protocol was approved by the ethics
committee of Tongji Medical College of Huazhong
University of Science and Technology.
Statistical analysis
All data were expressed as the mean ± standard error.
Statistical analysis between groups was calculated by
student’s t-test. P value <0.05 was considered statistically
significant.
Conclusions
Expression of DACH1 was significantly decreased in
human renal carcinoma tissue and was inversely correlated
with proliferation, tumor grade, and TNM stage. Restor-
ation of DACH1 function in renal clear cell cancer cells
inhibited in vitro cellular proliferation and in vivo tumor
growth. The repression of cyclin D1 transcription was a key
target of DACH1 in regulating cancer cell proliferation. Our
results indicated that DACH1 attributed to the malignant
behavior of renal cancer cells. Re-activation of DACH1 may
represent a potential therapeutic strategy.
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